17th Mar 2006 07:02
Ardana PLC17 March 2006 Ardana appoints Klaus Falk as VP Sales & Marketing Edinburgh, UK, 17 March 2006; Ardana plc (LSE:ARA) the emerging pharmaceuticalcompany focused on improving human reproductive health, announces theappointment of Klaus Falk as Vice President, Sales & Marketing. Mr Falk, aged 46, has over 20 years of experience in the pharmaceuticalindustry, gained at Merck KGaA in a number of posts including 8 years as aGeneral Manager in Central and South America. Whilst based in Germany, he gainedexperience in a range of strategic projects including M&A and the company's IPOin 1995. As Vice President, Europe, he was responsible for Sales & Marketing andhis achievements included the successful launch of the oncology franchise'sfirst product, Erbitux, in 2003. Commenting, Dr Maureen Lindsay, Ardana's CEO, said, "Klaus's deep and broadexperience over the last 20 years will bring significant benefits to Ardana aswe build further on our sales and marketing capabilities in the UK and Europe.With Striant on the market; a planned launch for Invicorp later this year, andvarious in-licensing opportunities, we are delighted that Klaus will be leadingthese key activities". For more information contact: Ardana Financial DynamicsMaureen Lindsay (corporate/financial media relations)Tel: + 44 (0) 131 226 8550 Julia Phillips/John Gilbert Tel: +44 (0)20 7831 3113 NB Public Relations trade/technical media relations) Nicki Brimicombe Tel: + 44 (0)1883 732353 About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development andmarketing of innovative products to improve human reproductive health, a $23.8billion market. Since its foundation, Ardana has maintained a broad and balanced portfolio tomanage risk and actively pursues product and technology in-licensing andout-licensing to maintain a robust pipeline. Ardana's four lead products are summarised below: • Striant(TM) SR, a testosterone replacement therapy for which Ardana has marketing rights in Europe, has already been launched by Ardana through its own sales force in the UK as a treatment for men with confirmed hypogonadism • Teverelix LA, in development for three initial indications: prostate cancer and benign prostatic hyperplasia (both indications are at the phase II stage), and endometriosis (currently in phase I) • Testo Cream, a transdermal testosterone delivery system in phase II for the treatment of male hypogonadism • Invicorp(R), an injectable combination drug treatment for erectile dysfunction, already approved in Denmark and for which Ardana has marketing and manufacturing rights in Europe. Launch is expected in H2 2006 In addition, Ardana has a strong portfolio of follow-on products in development.Ardana completed its IPO on the London Stock Exchange in March 2005 raising£21 million. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Aura Renew Acq